4Sheard NF,Clark NG,Brand-Miller JC,et al.Dietat T carbohydrate(a-mount and type)in the prevention and management of diabetes:a state-ment by the American Diabetes Association[J].Diabetes Care,2004;27(9):2266-71.
6[2]Klang MJ,Caballer B,Appel LJ,et al.plasma insulin level and incidence of hyupertension in Afriesn Americans and whites,Arch Msed,1999 159;498-503.
7Olbrot M, Rud J, Moss LG, et al. Identification of beta- cell-specific insulin gene transcription factor RIPE3bl as mammalian MafA [ J ]. Proc Natl Acad Sci USA, 2004,99(10) :6734-6742.
8Seufert J, Weir, GC, Habener JF. Differential expression of the insulin gene transcriptional repressor CCAAT/ enhancer-binding protein beta and transactivator islet duodenum homeobox-1 in rat pancreatic beta cells during the development of diabetes mellitus [ J ]. J Clin Invest, 1998,101 ( 11 ) :2528-2539.
9Vanderford NL. The role of MafA in regulating cytokine expression in pancreatic beta ceils [ J ]. J Biol Chem, 2011,286(3) :11-22.
10Abderrahmani A, Cheviet S, Ferdaoussi M, et al. ICER induced by hyperglycemia represses the expression of genes essential for insulin exocytosis [ J ]. EMBO J, 2006,25 ( 5 ) :977-986.
1Adem Karahoca.Dosage planning for type 2 diabetes mellitus patients using lndexingHDMR[J].ExpertSyste with Application,2012,39(8):7207- 7215.
2Davies M.J,Chubb B.D.,Smith I.C.,et aI.Cost-utility analysis of liraglu- tide compared with sulphonylurea or sitagliptin, all as add-on to met- fonnin monotherapy in Type2 diabetes mellitus[J].Diabetic medicine, 2012,29(3):313-320.
3Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes [ J ]. Diabetes, 2002, 51 (6): 1889-1895.
4Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new - onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C - reactive protein in the west of Scotland coronary prevention study [ J ]. Diabetes, 2004, 53 (11): 2855-2860.
5Gupte P, Amarapurkar D, Agal S, et al. Non - alcoholic steatohepatitis in type 2 diabetes rnellitus [ J ]. J Gastroenteml Hepatol, 2004, 19:854 -858.
6Fargher G, Bertolini L, Poll F, et al. Nonalcoholic fatty liver lisease and risk of future cardiovascular events among type 2 diabetic mtients [J]. Diabetes, 2005, 54 (12): 3541-3546.
7Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease among type 2 diabetic patients with non - alcoholic fatty liver disease [ J]. Diabet Med, 2006,23 (4) :403 - 409.
8American Diabetes Association. Standards of medical care in diabetes 2012 [ J]. Diabetes Care, 2012, 35 ( Suppl 1 ) : $11 -63.
9Abdul- Ghani MA, Matsuda M, Balas B, et al. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test [J]. Diabetes Care, 2007, 30 (1): 89-94.
10Matsuda M, Defronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp [J]. Diabetes Care, 1999, 22 (9) : 1462 -1470.
